ClinicalTrials.gg
TerminatedNCT00524030Updated Jan 20, 2021Results posted

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

A Phase 3 interventional study of pregabalin 600 mg/day and pregabalin 150 mg/day in Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 73 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-20.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.

Enrollment
11th of 18
161 · median 244
Started
2007
with 4 others
Phase 3
12 of 18
none open now
Registered
12th of 18
by date
Lead sponsor
10 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 11th largest by enrollment, is one of 5 that started in 2007, is one of 12 in phase 3, and was the 12th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing pregabalin in Epilepsies, Partial as a file.
02

Study summary

This study will determine the safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy subjects for the treatment of partial seizures. The duration of the trial is about 6 months.

Read the detailed description

After review of the interim analysis results, the independent Data Monitoring Committee (DMC) recommended to stop the study based on positive efficacy findings for the primary efficacy endpoint according to pre-specified stopping rules. Pfizer accepted the DMC recommendation and made the decision to stop the study on September 7, 2011.

03

Conditions studied

  • Epilepsies, Partial

Keywords

  • Epilepsy
  • partial seizures
  • pregabalin monotherapy
  • double-blind and randomized trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of epilepsy with partial seizures.
  • Males or females, age 18 years or older.
  • Documented history of at least 4 partial seizures in the 8 weeks prior to the screening visit.
  • Stable treatment with 1 to 2 anti-epileptic drugs in the 8 weeks prior to the screening visit.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of febrile seizures or seizures related to an ongoing acute medical event.
  • Seizures occurring only in cluster patterns, or seizures of a metabolic, toxic or infectious origin.
  • Primary generalized epilepsy or status epilepticus within the previous year.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    1

    Drug: pregabalin 600 mg/day

  • Experimental
    2

    Drug: pregabalin 150 mg/day

Interventions

  • Drugpregabalin 600 mg/day

    Drug page: Pregabalin

    pregabalin 600 mg/day (300mg BID), duration is 20 weeks.

  • Drugpregabalin 150 mg/day

    Drug page: Pregabalin

    pregabalin 150 mg/day (75mg BID), duration is 20 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria

    Participants who discontinued due to: episode of status epilepticus (SE); secondarily generalized tonic-clonic (SGTC) seizure if none within 2 years of study entry; 28-day study seizure rate during double-blind phase (DBP) greater than (\>)2 times maximum (Max) 28-day study seizure rate during baseline phase (BLP); 2-day study seizure rate during DBP \>2 times Max 2-day study seizure rate during BLP; or unacceptable clinically significant increase in frequency/intensity of seizure activity. Determined as exit rate:(1-Kaplan-Meier \[KM\] product limit estimate for survival function) \* 100%

    Time frame: Week 2 up to Week 18

Secondary outcomes

  1. Percentage of Participants in the Pregabalin 150 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria

    Participants who discontinued due to: episode of SE; SGTC seizure if none within 2 years of study entry; 28-day study seizure rate during DBP \>2 times Max 28-day study seizure rate during BLP; 2-day study seizure rate during DBP \>2 times Max 2-day study seizure rate during BLP; or unacceptable clinically significant increase in frequency/intensity of seizure activity. Determined as exit rate, defined as (1-KM product limit estimate for survival function) \* 100%

    Time frame: Week 2 up to Week 18

  2. Percentage of Participants Completing 20 Weeks of Double-Blind Treatment

    Time frame: Randomization up to Week 20

  3. Percentage of Participants Who Met Protocol-Specified Exit Events

    Percentage of participants experiencing any of the following (could have had more than 1): 1) episode of SE; 2) SGTC seizure if none had been experienced within 2 years of study entry; 3) 28-day study seizure rate during DBP \>2 times the Max 28-day study seizure rate during BLP; 4) 2-day study seizure rate during the DBP \>2 times the Max 2-day study seizure rate during BLP; or 5) unacceptable clinically significant increase in frequency/intensity of seizure activity

    Time frame: Week 2 up to Week 18

  4. Mean Time on Pregabalin Monotherapy

    Time frame: Week 2 to Week 20

  5. Percentage of Seizure-Free Participants by Study Phase

    Percentage of participants who were seizure-free during the last 28 days on double-blind study medication (monotherapy phase, Days 112-140), during the monotherapy portion of the double-blind treatment phase (Days 56-140), and during all of the double-blind treatment phase (Days 1-140)

    Time frame: Day 1 up to Day 140

  6. Pregabalin Population Pharmacokinetics (PK)

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Baseline up to 20 weeks

  7. Pregabalin Exposure-Response Analysis

    Percentage of participants predicted to exit the study due to any seizure exit criteria at Day 126. The exit rate at Day 126 was predicted using the final model (log normal distribution with respect to treatment group) and the parameter estimates.

    Time frame: Day 126

07

Results

Posted May 10, 2012
Limitations and caveats
External Data Monitoring Committee (DMC) determined study met criteria to stop early for positive efficacy. Exit rate was the basis for primary analysis and is what is reported here.

Participant flow

Participant flow — Overall Study
MilestonePregabalin 150 mg/DayPregabalin 600 mg/Day
Started32129
Completed double-blind treatment phase1570
Completed taper/titration phase1570
Completed1570
Not completed1759
Withdrew: Lack of efficacy1024
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject38
Withdrew: Noncompliance/investigator discretion02
Withdrew: Protocol violation01
Withdrew: Pregnancy10
Withdrew: Adverse event321
Withdrew: Death01

Outcome measures

PrimaryPercentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria

Participants who discontinued due to: episode of status epilepticus (SE); secondarily generalized tonic-clonic (SGTC) seizure if none within 2 years of study entry; 28-day study seizure rate during double-blind phase (DBP) greater than (\>)2 times maximum (Max) 28-day study seizure rate during baseline phase (BLP); 2-day study seizure rate during DBP \>2 times Max 2-day study seizure rate during BLP; or unacceptable clinically significant increase in frequency/intensity of seizure activity. Determined as exit rate:(1-Kaplan-Meier \[KM\] product limit estimate for survival function) \* 100%

Time frame:
Week 2 up to Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria
Percentage of ParticipantsPregabalin 600 mg/Day
Percentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria31.9 (20.7 to 43.1)
Statistical analysis
  • Pregabalin 600 mg/Day · Wald Test · p = <0.0012-sided 95% adjusted confidence interval constructed using KM product limit estimation and Greenwood's formula for variance with continuity correction
  • Pregabalin 600 mg/Day · Wald Test · p = <0.0012-sided 95% adjusted confidence interval constructed using KM product limit estimation and Greenwood's formula for variance with continuity correction
SecondaryPercentage of Participants in the Pregabalin 150 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria

Participants who discontinued due to: episode of SE; SGTC seizure if none within 2 years of study entry; 28-day study seizure rate during DBP \>2 times Max 28-day study seizure rate during BLP; 2-day study seizure rate during DBP \>2 times Max 2-day study seizure rate during BLP; or unacceptable clinically significant increase in frequency/intensity of seizure activity. Determined as exit rate, defined as (1-KM product limit estimate for survival function) \* 100%

Time frame:
Week 2 up to Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants in the Pregabalin 150 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria
Percentage of ParticipantsPregabalin 150 mg/Day
Percentage of Participants in the Pregabalin 150 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria37.7 (15.4 to 60)
Statistical analysis
  • Pregabalin 150 mg/Day · Wald test · p = <0.0012-sided 95% adjusted confidence interval constructed using KM product limit estimation and Greenwood's formula for variance with continuity correction
  • Pregabalin 150 mg/Day · Wald test · p = 0.0012-sided 95% adjusted confidence interval constructed using KM product limit estimation and Greenwood's formula for variance with continuity correction
SecondaryPercentage of Participants Completing 20 Weeks of Double-Blind Treatment
Time frame:
Randomization up to Week 20
Reported as:
Number · Percentage of Participants
Percentage of Participants Completing 20 Weeks of Double-Blind Treatment
Percentage of ParticipantsPregabalin 150 mg/DayPregabalin 600 mg/Day
Percentage of Participants Completing 20 Weeks of Double-Blind Treatment53.658.3
SecondaryPercentage of Participants Who Met Protocol-Specified Exit Events

Percentage of participants experiencing any of the following (could have had more than 1): 1) episode of SE; 2) SGTC seizure if none had been experienced within 2 years of study entry; 3) 28-day study seizure rate during DBP \>2 times the Max 28-day study seizure rate during BLP; 4) 2-day study seizure rate during the DBP \>2 times the Max 2-day study seizure rate during BLP; or 5) unacceptable clinically significant increase in frequency/intensity of seizure activity

Time frame:
Week 2 up to Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Met Protocol-Specified Exit Events
Percentage of ParticipantsPregabalin 150 mg/DayPregabalin 600 mg/Day
Status Epilepticus01.0
SGTC Seizure (not experienced in previous 2 years)02.9
28-Day Seizure Rate >2 times Max Baseline Rate13.010.8
2-Day Seizure Rate >2 times Max Baseline Rate13.07.8
Increased Frequency/Intensity of Seizure Activity17.414.7
Total39.128.4
SecondaryMean Time on Pregabalin Monotherapy
Time frame:
Week 2 to Week 20
Reported as:
Mean · Days
Mean Time on Pregabalin Monotherapy
DaysPregabalin 150 mg/DayPregabalin 600 mg/Day
Mean Time on Pregabalin Monotherapy73.8 ± 30.1578.0 ± 28.24
SecondaryPercentage of Seizure-Free Participants by Study Phase

Percentage of participants who were seizure-free during the last 28 days on double-blind study medication (monotherapy phase, Days 112-140), during the monotherapy portion of the double-blind treatment phase (Days 56-140), and during all of the double-blind treatment phase (Days 1-140)

Time frame:
Day 1 up to Day 140
Reported as:
Number · Percentage of Participants
Percentage of Seizure-Free Participants by Study Phase
Percentage of ParticipantsPregabalin 150 mg/DayPregabalin 600 mg/Day
Last 28 Days of Monotherapy (Days 112-140)17.912.5
Monotherapy (Days 56-140)7.16.7
Entire Double-Blind Treatment (Days 1-140)01.7
SecondaryPregabalin Population Pharmacokinetics (PK)

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Baseline up to 20 weeks

No measurements were reported for this outcome.

SecondaryPregabalin Exposure-Response Analysis

Percentage of participants predicted to exit the study due to any seizure exit criteria at Day 126. The exit rate at Day 126 was predicted using the final model (log normal distribution with respect to treatment group) and the parameter estimates.

Time frame:
Day 126
Reported as:
Number · Percentage of Participants
Pregabalin Exposure-Response Analysis
Percentage of ParticipantsPregabalin 150 mg/DayPregabalin 600 mg/Day
Pregabalin Exposure-Response Analysis37.226.3

Adverse events

Collected over Baseline to Week 21. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin 150 mg/Day—1/32 (3.1%)15/32 (46.9%)
Pregabalin 600 mg/Day—17/129 (13.2%)75/129 (58.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPregabalin 150 mg/DayPregabalin 600 mg/Day
ConvulsionNervous system disorders0/325/129
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/320/129
PneumoniaInfections and infestations0/322/129
Grand mal convulsionNervous system disorders0/322/129
Angina pectorisCardiac disorders0/321/129
Cardio-respiratory arrestCardiac disorders0/321/129
Abdominal painGastrointestinal disorders0/321/129
Chest painGeneral disorders0/321/129
Meningitis bacterialInfections and infestations0/321/129
Complex partial seizuresNervous system disorders0/321/129
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPregabalin 150 mg/DayPregabalin 600 mg/Day
DizzinessNervous system disorders5/3225/129
SomnolenceNervous system disorders5/3222/129
Weight increasedInvestigations2/3221/129
FatigueGeneral disorders2/3220/129
HeadacheNervous system disorders0/3213/129
Disturbance in attentionNervous system disorders3/324/129
Dry mouthGastrointestinal disorders2/322/129
Alanine aminotransferase increasedInvestigations2/321/129
DysarthriaNervous system disorders2/322/129
Vision blurredEye disorders1/328/129

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pregabalin 150 mg/DayPregabalin 600 mg/DayTotal
Mean35.2 ± 12.439.9 ± 13.239.0 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin 150 mg/DayPregabalin 600 mg/DayTotal
Female187189
Male145872
08

Study locations

73 sites
  • Pfizer Investigational Site
    Northport, Alabama 35476, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85003, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85013, United States
  • Pfizer Investigational Site
    Sun City, Arizona 85351, United States
  • Pfizer Investigational Site
    Fayetteville, Arkansas 72703, United States
  • Pfizer Investigational Site
    Fullerton, California 92835, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Modesto, California 95355, United States
  • Pfizer Investigational Site
    Murrieta, California 92562, United States
  • Pfizer Investigational Site
    Newport Beach, California 92660, United States
  • Pfizer Investigational Site
    Temecula, California 92591, United States
  • Pfizer Investigational Site
    Denver, Colorado 80204, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32209, United States
  • Pfizer Investigational Site
    Melbourne, Florida 32901, United States
  • Pfizer Investigational Site
    Miami, Florida 33126, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Sarasota, Florida 34232, United States
  • Pfizer Investigational Site
    Sarasota, Florida 34233, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30309, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30342, United States
  • Pfizer Investigational Site
    Decatur, Georgia 30033, United States
  • Pfizer Investigational Site
    Lawrenceville, Georgia 30045, United States
  • Pfizer Investigational Site
    Suwanee, Georgia 30024, United States
  • Pfizer Investigational Site
    Anderson, Indiana 46016, United States
  • Pfizer Investigational Site
    Danville, Indiana 46122, United States
  • Pfizer Investigational Site
    Fort Wayne, Indiana 46805, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66160, United States
  • Pfizer Investigational Site
    Bowling Green, Kentucky 42101, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40536-0284, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40536, United States
  • Pfizer Investigational Site
    Houma, Louisiana 70363, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71105-5634, United States
  • Pfizer Investigational Site
    Pikesville, Maryland 21208, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01605, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01608, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48202, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55422, United States
  • Pfizer Investigational Site
    Flowood, Mississippi 39232, United States
  • Pfizer Investigational Site
    Hattiesburg, Mississippi 39401-7246, United States
  • Pfizer Investigational Site
    Great Falls, Montana 59405, United States
  • Pfizer Investigational Site
    Cedarhurst, New York 11516, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28207, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28209, United States
  • Pfizer Investigational Site
    Rocky Mount, North Carolina 27804, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210-1250, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • Pfizer Investigational Site
    Altoona, Pennsylvania 16602, United States
  • Pfizer Investigational Site
    Indiana, Pennsylvania 15701, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38120, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38163, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    Houston, Texas 77074-2906, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78258, United States
  • Pfizer Investigational Site
    Temple, Texas 76508, United States
  • Pfizer Investigational Site
    Murray, Utah 84107, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84107, United States
  • Pfizer Investigational Site
    West Jordan, Utah 84088, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • Pfizer Investigational Site
    Beroun, 266 01, Czechia
  • Pfizer Investigational Site
    Brno 2, 602 00, Czechia
  • Pfizer Investigational Site
    Litomysl, 570 14, Czechia
  • Pfizer Investigational Site
    New Territories, Hong Kong
  • Pfizer Investigational Site
    Dnipropetrovsk, 49027, Ukraine
  • Pfizer Investigational Site
    Dnipropetrovsk, 49115, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 61018, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 61068, Ukraine
  • Pfizer Investigational Site
    Lugansk, 91045, Ukraine
  • Pfizer Investigational Site
    Odessa, 65025, Ukraine
09

References and documents

Publications

  • French J, Kwan P, Fakhoury T, Pitman V, DuBrava S, Knapp L, Yurkewicz L. Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial. Neurology. 2014 Feb 18;82(7):590-7. doi: 10.1212/WNL.0000000000000119. Epub 2014 Jan 10. PubMed 24415567 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Apr 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2007
First posted
Sep 3, 2007
Start
Sep 2007
Primary completionActual
Apr 2011
CompletionActual
Jun 2011
Results first posted
May 10, 2012
Last update
Jan 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00524030
Responsible party
Sponsor
First posted
Sep 3, 2007
Start date
Sep 2007
Primary completion
Apr 2011
Completion
Jun 2011
Results posted
May 10, 2012
Last update
Jan 20, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion